Medication Considerations in Transfusion-Dependent Thalassemia

Iron Chelation Therapy

• Deferiprone may increase the risk of neutropenia and should be used with caution, particularly during concurrent antiviral therapy, in patients with transfusion-dependent thalassemia, according to the American Society of Hematology 1
• The European Hematology Association recommends switching to deferoxamine during HCV antiviral treatment rather than continuing deferiprone or deferasirox, as safety data for deferasirox with combination antiviral therapy is lacking, in patients with transfusion-dependent thalassemia 1

Cardiac Medications in Iron-Overloaded Patients

• The American Heart Association advises that patients with decompensated myocardiopathy or severe cardiac rhythm disorders should be excluded from certain antiviral treatments due to the risk of cardiac decompensation, in the context of iron overload in transfusion-dependent thalassemia patients 4, 5
• The American College of Cardiology recommends that amiodarone can be used for atrial arrhythmias in iron-overloaded patients, but may cause hypothyroidism due to iron-mediated thyroid damage, in patients with transfusion-dependent thalassemia 5

Growth Factors

• The National Institute of Diabetes and Digestive and Kidney Diseases states that erythropoietin is not advised during antiviral combination therapy in transfusion-dependent patients, due to potential adverse effects 1